Pharmaceuticals
KLN Appointed by Ego Pharmaceuticals as 4PL Partner in Hong Kong Strategic Collaboration to Deliver End-to-End Healthcare Supply Chain Solutions
HONG KONG, Nov. 5, 2025 /PRNewswire/ -- KLN Logistics Group Limited ('KLN'; Stock Code 0636.HK) is pleased to announce the appointment of its pharmaceutical arm, KLN Pharma (Hong Kong) Limited ('KLN Pharma'), as the fourth-party logistics (4PL) service provider for Australian skincare brand Ego ...
2025-11-05 13:42
1415
Ascletis Presents Full Analysis of Phase Ib Study of ASC30 Oral Tablet, Phase Ib Study of ASC30 Injection, and Preclinical Study of Combination of ASC31 and ASC47 at ObesityWeek® 2025
-Positive data from Phase Ib study of ASC30 oral tablet demonstrated up to 6.5% placebo-adjusted mean body weight reduction; safe and well tolerated with only mild-to-moderate gastrointestinal (GI) adverse events (AEs) across all multiple ascending dose (MAD) cohorts. -Phase Ib study data of ASC...
2025-11-05 08:10
2406
Grit Biotherapeutics Invited to Deliver Oral Presentation at ASH 2025 on Breakthrough In Vivo CAR-T Therapy GT801
BEIJING, Nov. 4, 2025 /PRNewswire/ -- Grit Biotherapeutics Co., Ltd. ("Grit Bio "), a leading clinical-stage biopharmaceutical company pioneering next-generation immunotherapies,today announced that its groundbreaking GT801 in vivo CAR-T program has been selected for an oral presentation at the u...
2025-11-04 21:15
2180
LakeShore Biopharma Enters into Definitive Agreement for Going-Private Transaction
BEIJING, Nov. 4, 2025 /PRNewswire/ -- LakeShore Biopharma Co., Ltd ("LakeShore Biopharma" or the "Company") (OTCPK: LSBCF; OTCPK: LSBWF), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics fo...
2025-11-04 20:04
4509
Hasten Sets a New Benchmark for Global Expansion by Building an End-to-End Asia-Pacific Healthcare Commercial Platform
SHANGHAI, Nov. 4, 2025 /PRNewswire/ -- Hasten Biopharmaceutical Co., Ltd. ("Hasten") announced that while completing 70 Marketing Authorization Transfers (MAT) for itsAsia-Pacific product portfolio, the company has established an end-to-end commercial network coveringSoutheast Asia, Australia, Ko...
2025-11-04 11:15
1503
Oral Presentation: Five Hematologic Malignancies Studies by Leads Biolabs to Be Featured at ASH 2025
NANJING, China, Nov. 4, 2025 /PRNewswire/ -- Leads Biolabs (Stock Code: 9887.HK) today announced that five research abstracts from its hematological oncology portfolio—including programs LBL–034 and LBL–076—have been accepted for presentation at the 67th Annual Meeting of the American Society of ...
2025-11-04 09:50
2695
CARsgen Announces Positive Clinical Data for Allogeneic CAR-T Products CT0596 and CT1190B
SHANGHAI, Nov. 3, 2025 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, announces clinical data for CT0596, an allogeneic BCMA-targeting CAR-T product candidate developed on its proprietary THANK-u Plus™ ...
2025-11-03 22:15
3318
EmeTerm Wristband Significantly Reduces Postoperative Nausea and Vomiting in Major Orthopedic Surgeries
VANCOUVER, BC, Nov. 3, 2025 /PRNewswire/ -- WAT Medical Enterprise Ltd. proudly announced the publication of a groundbreaking clinical trial inThe Journal of Bone & Joint Surgery (JBJS) which demonstrates the significant benefits of the EmeTerm wristband in reducing postoperative nausea and vomit...
2025-11-03 22:00
2689
Sanyou Bio and Shanghai ZJ Bio-Tech Sign Strategic Cooperation Agreement on Automated Development of Innovative Biologics to Jointly Tackle R&D Bottlenecks and Provide New Momentum for Innovative Drug R&D
SHANGHAI, Nov. 3, 2025 /PRNewswire/ -- Sanyou Biopharmaceuticals (Shanghai) Co., Ltd. (hereinafter referred to as "Sanyou Bio") and Shanghai ZJ Bio-Tech technology Co., Ltd. (hereinafter referred to as "Shanghai ZJ Bio-Tech") jointly announced the official signing of a strategic cooperation agree...
2025-11-03 22:00
3274
Samsung Biologics completes spin-off to strengthen its focus as a pure-play CDMO
* Spin-off finalized within five months following board resolution * Proposal approved in shareholders' meeting with 99.9% support * Company to reaffirm its identity as a pure-play CDMO INCHEON, South Korea, Nov. 3, 2025 /PRNewswire/ -- Samsung Biologics (KRX: 207940.KS) today announced the ...
2025-11-03 20:00
3949
Novo Nordisk Launches Wegovy® in Hong Kong for Weight Management
* Wegovy® (semaglutide) is a once-weekly injectable prescription medicine used in combination with a reduced calorie diet and increased physical activity for adults and adolescents aged 12 years old or above with obesity or adults with overweight in the presence of at least one related health c...
2025-11-03 16:48
1924
GC Biopharma's Recombinant Anthrax Vaccine, BARYTHRAX, Demonstrates Safety and Immunogenicity in Phase 2 Data, Published in 'Vaccine'
YONGIN, South Korea, Nov. 3, 2025 /PRNewswire/ -- GC Biopharma, a leading global pharmaceutical company based inSouth Korea, announced today that the Phase 2 clinical trial results for its anthrax vaccine 'BARYTHRAX inj. (GC1109)' have been published in the international journal Vaccine. BARYTHRA...
2025-11-03 13:26
2436
Akeso's Ivonescimab Secures Fourth Breakthrough Therapy Designation in China for First-Line Treatment of Triple-Negative Breast Cancer
HONG KONG, Nov. 2, 2025 /PRNewswire/ -- Akeso (9926.HK) announced that its first-in-class bispecific antibody, ivonescimab (PD-1/VEGF bispecific antibody), in combination with chemotherapy for first-line treatment of triple-negative breast cancer (TNBC) has been granted Breakthrough Therapy Desi...
2025-11-03 12:12
1738
Zhimeng Biopharma's investigational drug CB03-154 for amyotrophic lateral sclerosis has achieved the first patient first dose milestone in the phase 2/3 pivotal clinical trial.
SHANGHAI, Oct. 31, 2025 /PRNewswire/ -- Shanghai Zhimeng Biopharma Inc. ( "Zhimeng") announced that its self-developed new-generation potassium channel opener CB03-154 for the treatment of amyotrophic lateral sclerosis (ALS) has officially initiated the phase 2/3 clinical trial and completed the ...
2025-10-31 21:00
2612
Alpha Fusion Initiates Company-Sponsored Clinical Trial of Alpha-Emitting Radiopharmaceutical af-001 in Patients with Differentiated Thyroid Cancer
– Aiming to establish af-001 as a new therapeutic option for radioactive iodine (RAI)-naïve patients with differentiated thyroid cancer – TOKYO, Oct. 31, 2025 /PRNewswire/ -- Alpha Fusion Inc. (Headquarters: Chiyoda-ku,Tokyo; CEO: Sunao Fujioka; hereinafter "Alpha Fusion") today announced the in...
2025-10-31 20:00
2203
Kexing Biopharm Showcases Global Strategy and Partnership Opportunities at CPHI Frankfurt 2025
FRANKFURT, Germany, Oct. 31, 2025 /PRNewswire/ -- From October 28th to 30th, Kexing Biopharm participated in CPHI Frankfurt 2025, one of the world's most influential pharmaceutical exhibitions, presenting its key product portfolio and international commercialization solutions to partners from glo...
2025-10-31 19:50
4551
NovaBridge Subsidiary Visara Assigns Its Exclusive License to Everest Medicines for VIS-101 in Greater China and Certain Other Asian Countries
* NovaBridge subsidiary Visara assigned its exclusive license to Everest Medicines to accelerate the development of potential best-in-class therapy for wet AMD, VIS-101, leveraging Everest Medicines' strong clinical and commercialization expertise inGreater China and other Asian markets * Nov...
2025-10-30 16:15
1684
U.S. FDA grants interchangeability designation to Celltrion's denosumab biosimilars, STOBOCLO® (denosumab-bmwo) and OSENVELT® (denosumab-bmwo)
* The U.S. FDA approved STOBOCLO® (denosumab-bmwo) and OSENVELT® (denosumab-bmwo) as interchangeable with the reference products PROLIA® (denosumab) and XGEVA® (denosumab), respectively, for all approved indications, effective as ofOctober 29, 2025 * The interchangeability (IC) designations o...
2025-10-30 15:28
3695
Everest Medicines Acquires Exclusive Greater China and Other Asian Country Rights to VIS-101, a Novel Bifunctional Biologic for Serious Eye Disorders
* Everest Medicines acquired an exclusive license to develop, manufacture, and commercialize VIS-101 inGreater China, Singapore, South Korea, and certain Southeast Asian countries. * Under the assigned exclusive license, Everest Medicines will make an upfront payment ofUS$7 million (equivalen...
2025-10-30 11:05
2221
LOTTE BIOLOGICS and SK pharmteco Sign Strategic Partnership to Strengthen Global ADC CDMO Capabilities
* Two global CDMO leaders have joined forces to strengthen their presence in the rapidly growing antibody-drug conjugate (ADC) market. * The collaboration will deliver integrated, one-stop CDMO services spanning antibody drug substance, linker–payload production, and bioconjugation, supported...
2025-10-30 09:15
5106
Week's Top Stories
Most Reposted
Visa and Trip.com Group Ink Strategic Collaboration, Enabling Consumers to Chase Their Passions Through Travel
[Picked up by 309 media titles]
2026-05-19 18:10
Two-day Global Prosperity Summit 2026 officially opens
[Picked up by 308 media titles]
2026-05-19 23:59
Two‑day Global Prosperity Summit 2026 concludes successfully
[Picked up by 303 media titles]
2026-05-21 22:13
Hyundai Motor Group to Pioneer Hong Kong's Hydrogen Economy, Accelerating Asia-Pacific Expansion
[Picked up by 290 media titles]
2026-05-18 15:30
Autonomous AI marketing platform Protaigé launches with Maia, the world's first AI Account Director that operates within the flow of work
[Picked up by 280 media titles]
2026-05-20 09:15Most Read
NYSE Content Update: Armada Raises $230 Million, Boosts Valuation to $2 Billion
2026-05-19 21:02
5709
/C O R R E C T I O N -- The American Chamber of Commerce in Singapore (AmChamSG)/
2026-05-21 12:14
5699
Scienjoy Holding Corporation Reports Unaudited First Quarter 2026 Financial Results
2026-05-21 20:30
5541
NYSE Content Update: Exchange Turns 234 Ahead of U.S. Semiquincentennial
2026-05-18 21:29
5441
